Augmentation of Apoptosis and Tumor Regression by Flavopiridol in the Presence of CPT-11 in Hct116 Colon Cancer Monolayers and Xenografts

• Published in: Clinical cancer research Vol. 7; no. 12; pp. 4209 - 4219
• Main Authors: MOTWANI, Monica, JUNG, Christoph, SIROTNAK, Francis M, YUHONG SHE, SHAH, Manish A, GONEN, Mithat, SCHWARTZ, Gary K
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.12.2001
• Subjects: Animals; Antineoplastic agents; Antineoplastic Agents - therapeutic use; Antineoplastic Agents, Phytogenic - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis - drug effects; Biological and medical sciences; Camptothecin - analogs & derivatives; Camptothecin - therapeutic use; Chemotherapy; Colonic Neoplasms - drug therapy; Colonic Neoplasms - pathology; Flavonoids - therapeutic use; Humans; Male; Medical sciences; Mice; Mice, Nude; Pharmacology. Drug treatments; Piperidines - therapeutic use; Transplantation, Heterologous; Tumor Cells, Cultured; Antineoplastic agent; Cell proliferation; Potentiation; Metabolite; Alkaloid; Isomerases; Cell cycle; Established cell line; Intestinal disease; Colon; Tumor cell; Human; Drug combination; Enzyme; Transferases; Treatment efficiency; Rodentia; DNA topoisomerase; Enzyme inhibitor; Malignant tumor; In vitro; Biological activity; Colonic disease; In vivo; Vertebrata; Chemotherapy; Mammalia; Treatment; Mouse; Cell death; Protein kinase; Animal; Digestive diseases; Apoptosis

CPT-11, a DNA topoisomerase I inhibitor, has demonstrated clinical activity in colorectal cancer. Flavopiridol, a cyclin-dependent kinase inhibitor, is rapidly emerging as a chemotherapy modulator. To enhance the therapeutic index of CPT-11 in colon cancer, we studied the combination of these two dr...